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Abstract The growth arrest after hypophysectomy in
rats is mainly due to growth hormone (GH) deﬁciency
because replacement of GH or insulin-like growth factor
(IGF) I, the mediator of GH action, leads to resumption
of growth despite the lack of other pituitary hormones.
Hypophysectomized (hypox) rats have, therefore, often
been used to study metabolic consequences of GH deﬁ-
ciency and its eﬀects on tissues concerned with growth.
The present study was undertaken to assess the eﬀects of
hypophysectomy on the serum and pancreatic levels of
the three major islet hormones insulin, glucagon, and
somatostatin, as well as on IGF-I. Immunohistochem-
istry (IHC), in situ hybridization (ISH), radio-
immunoassays (RIA), and Northern blot analysis were
used to localize and quantify the hormones in the pan-
creas at the peptide and mRNA levels. IHC showed
slightly decreased insulin levels in the b cells of hypox
compared with normal, age-matched rats whereas glu-
cagon in a cells and somatostatin in d cells showed in-
crease. IGF-I, which localized to a cells, showed
decrease. ISH detected a slightly higher expression of
insulin mRNA and markedly stronger signals for gluca-
gon and somatostatin mRNA in the islets of hypox rats.
Serum glucose concentrations did not diﬀer between the
two groups although serum insulin and C-peptide were
lower and serum glucagon was higher in the hypox
animals. These changes were accompanied by a more
than tenfold drop in serum IGF-I. The pancreatic insulin
content per gram of tissue was not signiﬁcantly diﬀerent
in hypox and normal rats. Pancreatic glucagon and
somatostatin per gram of tissue were higher in the hypox
animals. The pancreatic IGF-I content of hypox rats was
signiﬁcantly reduced. Northern blot analysis gave a 2.6-,
4.5-, and 2.2-fold increase in pancreatic insulin, gluca-
gon, and somatostatin mRNA levels, respectively, in
hypox rats, and a 2.3-fold decrease in IGF-I mRNA
levels. Our results show that the fall of serum IGF-I after
hypophysectomy is accompanied by a decrease in pan-
creatic IGF-I peptide and mRNA but by partly discor-
dant changes in the serum concentrations of insulin and
glucagon and the islet peptide and/or mRNA content of
the three major islet hormones. It appears that GH
deﬁciency resulting in a ‘‘low IGF-I state’’ aﬀects trans-
lational eﬃciency of these hormones as well as their
secretory responses. The maintenance of normoglycemia
in the presence of reduced insulin and elevated glucagon
serum levels, both of which would be expected to raise
blood glucose, may result mainly from the enhanced
insulin sensitivity, possibly due to GH deﬁciency and the
subsequent decrease in IGF-I production.
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Introduction
Growth hormone (GH) is the major regulator of post-
natal growth. The removal of the pituitary gland in
young growing rats leads to growth arrest. This appears
to be mainly caused by the lack of GH because
replacement of GH (Simpson et al. 1949; Guler et al.
1989) or insulin-like growth factor (IGF) -I (Guler et al.
1989) leads to resumption of growth despite the lack of
other pituitary hormones. Hypophysectomized (hypox)
rats therefore lend themselves to study the consequences
of GH deﬁciency on tissues concerned with growth and
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on metabolism. However, studies dealing with the eﬀects
of hypophysectomy on pancreatic hormones are some-
times diﬃcult to compare and/or are partly controver-
sial. Thus, the insulin content per gram of tissue in the
pancreas of hypox rats was found to be unchanged but
decreased when expressed per whole pancreas (Malaisse
et al. 1968). The insulin content expressed per islet of
cultured islets from hypox rats was reported to be un-
changed (Pierluissi et al. 1980). In contrast, islets iso-
lated and cultured 4 weeks after hypophysectomy
contained less insulin per microgram of protein than
islets from normal rats (Martin and Gagliardino 1967).
Pancreatic somatostatin per gram of tissue was found to
be unchanged (Berelowitz et al. 1981) whereas Recant
et al. (1984) found elevated somatostatin whether ex-
pressed per milligram of protein or per whole pancreas
of hypox rats. To our knowledge, no data are available
regarding pancreatic glucagon content in hypox rats.
Serum glucagon content in hypox rats has been reported
in only one study, where it was found to be elevated
(Van Lan et al. 1974). Furthermore, we are not aware of
any data on islet hormone gene expression in the pan-
creas of hypox rats. Above all, no study has investigated
the consequences of hypophysectomy in rats on the three
major pancreatic hormones insulin, glucagon, and
somatostatin, simultaneously at the peptide and mRNA
levels and compared immunohistochemical (IHC) with
radioimmunological determinations or in situ hybrid-
ization (ISH) with Northern blot analysis. Therefore, the
aim of our study was to combine these methodologies in
order to look for potential changes of these pancreatic
hormones following hypophysectomy in rats and to
localize these changes within the pancreatic islets.
Materials and methods
Animals
The experiments were approved by the Institutional
Animal Welfare Committee. Seven-week-old, normal
(n=6), hypophysectomized (hypox; n=6) male Wistar
rats (150–160 g) were obtained from Charles River
Laboratories (Charles River, Iﬀa Credo, France). The
rats were kept at 25C on a 12-h light/12-h dark cycle
and had free access to food and drinking water.
Tissue sampling
Two weeks after hypophysectomy, the rats were anes-
thetized with pentothal (Abbott Laboratories S.A, Baar,
Switzerland) and bled by aortic puncture. Blood samples
were collected on ice and, after clotting, centrifuged for
30 min at 3,000 g at 4C. The serum was stored at
20C for further analysis. The pancreas was excised,
weighed, and divided into three parts for (1) ﬁxation for
ISH and immunohistochemistry, (2) RNA extraction,
and (3) peptide extraction. Pancreas specimens were
ﬁxed in Bouin’s solution without acetic acid for 4 h and
embedded in paraﬃn. Total RNA was extracted imme-
diately after removal of the tissue using the extraction
solution provided with the RNA extraction kit (Nucle-
oSpin RNA II, Machery-Nagel, Du¨ren, Germany) and
stored at 80C until use. Tissue for protein extraction
was stored at 80C until use.
Immunohistochemical protocol
Sections were cut at 4 lm, deparaﬃnized in xylol,
rehydrated through a series of descending concentra-
tions of ethanol, and rinsed in deionized water. Non-
speciﬁc binding was reduced by treatment of the sections
with phosphate buﬀered saline (PBS) containing 2%
bovine serum albumin (BSA) for 30 min at room tem-
perature. Thereafter, the sections were incubated with
rabbit antisera directed against porcine glucagon (code
A565, 1:2000; Dako, Carpinteria, CA, USA), human (h)
somatostatin (code AO566, 1:300; Dako), or hIGF-I
(Maake and Reinecke 1993; Zapf et al. 2002; 1:300),
respectively, for 18 h at 4C. After rinsing in PBS/2%
BSA, the antisera were visualized by incubation for 2 h
at room temperature with ﬂuorescein-isothiocyanate
(FITC)-labeled goat antirabbit IgG (1:100; Dako). For
the detection of insulin, sections were incubated for 18 h
at 4C with a guinea pig antiserum against porcine
insulin (code A564; 1:18,000; Dako), washed three times
with PBS/2% BSA, and treated with biotinylated goat
antiguinea pig IgG (1:100; Bioscience, Emmenbru¨cke,
Switzerland) followed by FITC-coupled streptavidin
(1:1000; Bioscience) for 30 min at room temperature.
For control incubations, the primary antisera were re-
placed by nonimmune sera or preabsorbed with the
respective antigens (0.4–40 lg peptide/ml diluted anti-
serum). The sections were mounted with glycergel
(Dako), examined, and photographed with a Zeiss axi-
oscope (Zeiss, Zu¨rich, Switzerland).
Preparation of digoxigenin (DIG)-labeled RNA probes
Pancreatic total RNA from normal rats was, in a ﬁrst
step, reverse transcribed by M-MLV reverse transcrip-
tase (Promega, Madison, WI, USA) in the presence of
oligo (dT) primer and 1· reaction buﬀer (5·=250 mM
Tris–HCl pH 8.3, 375 mM KCl, 15 mM MgCl2, and
50 mM DTT) to generate cDNA. For the generation of
the insulin cDNA probe, cDNA was subjected to poly-
merase chain reaction (PCR) using the sense primer 5¢-
CAGCACCTTTGTGGTTCTCA-3¢ and the antisense
primer 5¢-AGGGTAGTGGTGGGCCTAGT-3¢, corre-
sponding to exon 2 and 3 in the rat insulin 2 gene
(GenBank Accession no. V01243 C06616). PCR was
performed in a GeneAmp PCR System 9600 cycler
(Perkin Elmer, Norwalk, CT, USA) in 1.5 mM MgCl2,
0.2 lM of each primer, 200 lM of each dNTP, and 1U
of Taq polymerase (Qbiogene Inc., Basel, Switzerland),
as recommended by the supplier. Ampliﬁcation condi-
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tions were optimized to reach linear PCR signals, i.e.,
one cycle of 5 min at 95C, 45 s at 58C, and 1 min at
72C; 33 cycles of 45 s at 95C, 45 s at 58C, and 1 min
at 72C followed by a ﬁnal extension step of 5 min at
72C. The PCR product was then analyzed by electro-
phoresis on 1.5% agarose gel and puriﬁed using a PCR
Puriﬁcation Kit (Qiagen, Basel, Switzerland), according
to the manufacturer’s instructions. The rat insulin
cDNA probe (267-bp fragment), thus obtained, was
then cloned in a PCR-Script SK (+) cloning vector that
contained a T7 RNA polymerase binding site adjacent
to the multiple cloning site using a commercial kit
(Stratagene, Heidelberg, Germany). The plasmid
containing the insulin cDNA fragment was linearized
by restriction enzyme Not I (Promega). Thereafter,
the insulin RNA probe was synthesized by in vitro
transcription using DIG RNA labeling kit and T7
RNA polymerase (Roche Inc., Rotkreuz, Switzerland).
For the generation of glucagon and somatostatin
cDNA probes, the cDNA was subjected to PCR using
speciﬁc primers for glucagon (sense primer
5¢-AACGAAGACAAACGCCATTC-3¢ and antisense
primer 5¢-GCCCAAGTTCCTCAGCTATG-3¢, corre-
sponding to the nucleotide sequence 138–428, GenBank
Accession no. NM 012707), and somatostatin (sense
primer 5¢-TGGCAGAACTGCTGTCTGAG-3¢ and
antisense primer 5¢-AACGCAGGGTCTAGTTGAGC-
3¢, corresponding to the nucleotide sequence 218–517,
GenBank Accession no. NM 012659) whereby the 5¢ end
of the antisense primers contained an additional se-
quence encoding for T7 RNA polymerase promoter
(Microsynth, Balgach, Switzerland). PCR ampliﬁcation
conditions were optimized to reach linear PCR signals,
as follows: one cycle of 1 min at 95C, 45 s at 59C
(glucagon) or 61C (somatostatin), and 1 min at 72C;
33 cycles of 45 s at 95C, 45 s at 59C (glucagon) or
61C (somatostatin), and 1 min at 72C followed by a
ﬁnal extension step of 5 min at 72C. The PCR products
were analyzed by electrophoresis on 1.5% agarose gel
and puriﬁed using a PCR Puriﬁcation Kit (Qiagen). For
synthesis of the DIG-labeled RNA probes, 200 ng of the
glucagon and somatostatin PCR products, respectively,
were in vitro transcribed using the DIG RNA labeling
kit and T7 RNA polymerase (Roche). Integrity of the
probes and eﬃciency of DIG-labeling were conﬁrmed by
gel electrophoresis and dot blot.
In situ hybridization protocol
Paraﬃn sections cut at 4 lm were mounted on Super-
Frost Plus slides (Menzel-Gla¨ser, Germany), and dried
overnight at 42C. After dewaxing in xylol and rehy-
dration, the sections were postﬁxed with 4% parafor-
maldehyde and 0.1% glutaraldehyde in 1· PBS. The
following steps were carried out with diethylpyrocar-
bonate (DEPC)-treated solutions (DEPC, Sigma, Swit-
zerland) in a humidiﬁed chamber: Sections were digested
with 0.02% proteinase K in 20 mM Tris–HCl, pH 7.4
containing 2 mM CaCl2 for 10 min at 37C to denature
proteins. Background reduction was achieved by treat-
ment of the sections with 1.5% triethanolamine and
0.25% acid anhydride for 10 min at room temperature.
The slides were incubated with 100 ll prehybridization
solution (50% formamide, 1· PBS, 2.5· Denhardt’s
solution, 25 mM EDTA, 275 lg/ml single-strand DNA,
and 250 lg/ml yeast transfer RNA) per section for 3 h at
60C (insulin), 58C (glucagon), and 54C (somato-
statin). The hybridization was carried out overnight at
the same temperatures with 50 ll hybridization buﬀer
containing 50% formamide, 1· PBS, 2· Denhardt’s
solution, transfer RNA (1.5 lg/ml), single-strand DNA
(200 lg/ml), 10 mM dithiothreitol, 20% dextran sulfate,
and 200 ng antisense DIG-labeled RNA probe (previ-
ously denatured for 5 min at 85C).
The slides were washed for 15 min at room temper-
ature in 2· SSC and for 30 min at speciﬁc hybridization
temperatures at descending concentrations of SSC (2, 1,
0.5, and 0.2·). DIG detection was performed according
to the manufacturer’s instructions. In brief, after treat-
ment of the sections with 1% blocking reagent (Roche)
in 100 mM Tris–HCl, pH 7.4 containing 150 mM NaCl,
the alkaline phosphatase-coupled anti-DIG antibody
was diluted 1:4,000 in blocking solution, and sections
were incubated for 1 h at room temperature in the dark.
After washing twice in 100 mM Tris–HCl, pH 7.4 con-
taining 150 mM NaCl for 15 min each time, sections
were treated with 100 mM Tris–HCl, pH 9.5 containing
5 mM levamisole, 0.1% gelatin, nitro blue tetrazolium
(188 lg/ml), and 5-bromo-4-chloro-3-indolyl-phosphate
(375 lg/ml). Color development was performed for 16 h
at room temperature. The color reaction was stopped by
rinsing the slides in tap water for at least 15 min. Sec-
tions were mounted with glycergel. Microscopic images
were obtained with a Zeiss axioscope.
Preparation of radioactively labeled cDNA probes
Pancreatic (glucagon and somatostatin cDNA probes)
and hepatic (IGF-I cDNA probe) total RNA from
normal rats were reverse transcribed, as described ear-
lier, to generate cDNA. For the generation of glucagon
and somatostatin cDNA probes, PCR was performed,
as already described, using the same primer sequences
with the diﬀerence that the 5¢ end of the antisense
primers did not contain a T7 RNA polymerase promoter
sequence. For the generation of radioactively labeled
IGF-I DNA probes, the sense primer 5¢-ACA-
TCATGTCGTCTTCACATC-3¢ and the antisense pri-
mer 5¢-GGTCTTGTTTCCTGCACTTC-3¢, spanning
the nucleotide sequence 38–395 (GenBank Accession no.
D00698), were used. Optimized PCR conditions were as
follows: one cycle of 1 min at 95C, 45 s at 60C, 1 min
at 72C; 35 cycles of 45 s at 95C, 40 s at 60C, 1 min at
72C followed by a ﬁnal extension step of 5 min at 72C.
The PCR products were analyzed by electrophoresis on
1.5% agarose gel and puriﬁed using a PCR Puriﬁcation
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Kit (Qiagen). The rat insulin cDNA probe (500-bp
fragment) was kindly provided by Dr. J.H. Nielsen
(Hagedorn Research Institute, Gentofte, Denmark). The
yeast 18S ribosomal cDNA probe was a kind gift from
Dr. Kalousek (University Hospital, Zu¨rich). The rat
insulin, glucagon, somatostatin, IGF-I, and yeast 18S
ribosomal cDNA probes were labeled by random primer
extension using a commercial kit (Boehringer Mann-
heim, Rotkreuz, Switzerland) and [a-32P] deoxy-CTP
(3,000 Ci/mmol; Amersham, Cardiﬀ, UK) to the speciﬁc
activities of 2–4·109 cpm/lg DNA following the man-
ufacturer’s instructions.
Northern blotting
Twenty micrograms of total RNA isolated from pan-
creatic tissue was heat-denatured at 65C for 15 min.
Thereafter, RNA samples were electrophoresed on 1%
agarose gel containing 2 M formaldehyde, transferred to
nylon membranes (Hybond-N, Amersham) by capillary
blotting, and ﬁxed by UV cross-linking. Membranes
were prehybridized at 42C in a solution containing 50%
(vol/vol) deionized formamide, 5· Denhardt’s solution
(Ficoll 0.02% wt/vol, and polyvinyl pyrrolidone 0.02%
wt/vol), 5· SSPE (20·: 3.6 M NaCl, 0.2 M sodium
phosphate, and 0.02 M EDTA, pH 7.7), 0.2% SDS, and
100 lg/ml heat-denatured salmon sperm DNA.
Hybridizations were performed in the same solution
with 2·107 cpm 32P-labeled cDNA probe for insulin,
glucagon, somatostatin, IGF-I, and 18S cDNA/mem-
brane. After 48 h of incubation at 42C, the membranes
were washed twice for 10 min at room temperature and
for 15 min at 54C (insulin, IGF-I), 51C (glucagon and
somatostatin), or 65C (18 S) in 0.1· SSC/0.1% SDS.
Membranes were then exposed at 80C to an X-Omat
AR-5 ﬁlm (Kodak, Rochester, NY, USA) in cassettes
equipped with intensifying screens to visualize
[32P]cDNA-mRNA hybrids. Levels of mRNA were
quantiﬁed by scanning densitometry using a Bio-Rad
video densitometer (Richmond, CA, USA). In between
consecutive hybridizations, the membranes were washed
with 0.1· SSC/0.1% SDS at 98C for 45 min to remove
the previous cDNA probe. Variations in gel loading
were corrected against 18S ribosomal RNA values.
Serum glucose analysis
Serum glucose was determined with a Beckman glucose
analyzer (Beckman Coulter, Fullerton, CA, USA).
Tissue extraction for radioimmunoassays
Pancreatic tissue, 50 mg, was homogenized using a
Polytron homogenizer (Kinematica, Luzern, Switzer-
land) in 1 ml ice-cold acidic alcohol (0.18 N HCl/70%
EtOH), incubated overnight at 4C, and centrifuged at
16,000 g for 5 min. The supernatants were used for
determination of insulin, glucagon, somatostatin and
IGF-I contents using speciﬁc radioimmunoassay (RIA).
Radioimmunoassays
All RIAs were performed according to manufacturers’
protocols. Serum levels were determined in the undiluted
samples. Serum and pancreatic insulin and glucagon
content and serum C-peptide levels were determined
with speciﬁc rat RIA kits (Linco Research, Inc., St.
Charles, MO, USA). For determination of pancreatic
insulin and glucagon contents, the extracts were diluted
1:2,000–1:4,000 in the assay buﬀer provided. The
somatostatin concentrations in pancreatic extracts were
determined (dilution 1:500) using a human somatostatin
RIA kit (EURO-Diagnostica, Malmo¨, Sweden). It was
not possible to measure serum somatostatin because this
assay would have required 5 ml of serum. Serum and
tissue IGF-I levels were determined by RIA after SepPak
C18 chromatography (Waters Corp., Milford, MA,
USA), as described previously (Boni-Schnetzler et al.
1999; Zapf et al. 2002). In brief, for determination of
serum IGF-I, 0.15 ml PBS containing 0.2% human ser-
um albumin (HSA), pH 7.4, was added to 0.1 ml serum.
For determination of pancreatic IGF-I, 0.5 ml of the
extract was lyophilized, dissolved in 0.25 ml of PBS/
0.2% HSA, and centrifuged. All samples were acid-
treated and run over SepPak C18 cartridges, according
to the protocol supplied by Immunonuclear (Stillwater,
MN, USA). After reconstitution with 1-ml PBS/0.2%
HSA for serum and 0.6 ml PBS/0.2% HSA for pancre-
atic extracts, samples were assayed at three diﬀerent
dilutions (1:5, 1:10, 1:20 for serum, and undiluted 1:2, 1:4
for pancreatic extracts) (Boni-Schnetzler et al. 1999;
Zapf et al. 2002). Then, 0.2 ml of samples or standards
(rat IGF-I from GroPep, Adelaide, SA, Australia) and
0.1 ml of IGF-I antiserum (ﬁnal dilution 1:20,000) were
preincubated for 24 h at 4C. Then, 25,000–35,000 cpm
of 125I-IGF-I (Anawa, Wangen, Switzerland, speciﬁc
activity 300–400 lCi/ll) was added to the ﬁnal incuba-
tion volume of 0.4 ml. The reaction mixture was then
incubated for another 24 h before precipitation with the
secondary antibody (goat antirabbit gamma globulin
antiserum) (Zapf et al. 1981). After centrifugation, the
pellet was counted in a gamma counter.
Determination of blood volume in pancreatic tissue
The amount of blood in the pancreas was determined
according to Hohorst et al. (1950) and has recently been
described by Jevdjovic et al. (2004).
Statistical analysis
All results are expressed as mean ± SEM. Statistical
analysis was performed by Student’s t test (signiﬁcance
level P<0.05) with a StatView 4.5 program (Abacus
Concepts, Inc., Berkeley, CA, USA).
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Results
Body and pancreatic weight
Normal (age-matched) rats weighed 225±6 g whereas
hypox rats weighed 153±4 g (mean ± SD). The mean
pancreatic weight of normal rats was 429±48 mg
and that of hypox rats was 278±22 mg (P<0.0001).
Distribution of insulin, glucagon, somatostatin,
and IGF-I peptide in rat pancreatic islets
Insulin immunoreactivity in the b cells was slightly
decreased in the islets of hypox (Fig. 1b) compared to
the normal (Fig. 1a) rats whereas glucagon immuno-
reactivity in the a cells (Fig. 2a) and somatostatin
immunoreactivity in the d cells (Fig. 3a) was more
pronounced in hypox rats (Figs. 2b, 3b). IGF-I
immunoreactivity was localized to a cells (Fig. 4a) and
was lower in islets of hypox rats (Fig. 4b).
Localization of insulin, glucagon, and somatostatin
mRNA
In situ hybridization showed more intense signals for
insulin (Fig. 1d), glucagon (Fig. 2d), and somatostatin
(Fig. 3d) mRNAs in the islets of hypox rats compared
with controls (Figs. 1c, 2c, 3c).
Fig. 1 Localization of insulin
peptide (a, b) and mRNA (c, d)
in normal (a, c) and
hypophysectomized (hypox) (b,
d) rats. Bar: 40 lm. Serum
insulin (e), C-peptide (f),
pancreatic insulin peptide
content (g), and insulin mRNA
levels (h) of normal and hypox
rats. Serum insulin, C-peptide,
and pancreatic insulin were
measured by speciﬁc rat insulin
and C-peptide RIA. Insulin
mRNA content was determined
by Northern blot analysis.
Insulin mRNA and 18S rRNA
signals are shown above the
corresponding columns for each
of the two groups (h). The
insulin mRNA signals were
normalized against the18S
rRNA signals and expressed
as relative levels. Columns
give the mean values (n=6),
and bars give the SEM.
Signiﬁcance levels are indicated
in e, f, and h
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Serum glucose
Serum glucose levels were not signiﬁcantly diﬀerent be-
tween normal and hypox rats (9.17±0.43 vs.
8.65±0.41 mmol/l, respectively).
Serum insulin and C-peptide concentrations
and pancreatic insulin peptide and mRNA levels
Serum insulin concentrations were lower
(162±25 pmol/l) in hypox than in normal rats
(330±45 pmol/l, P=0.0086; Fig. 1e). The decrease in
serum insulin after hypophysectomy was accompanied
by a decrease in serum C-peptide concentrations from
858±67 pmol/l to 377±57 pmol/l (P=0.0003; Fig. 1f).
There was no signiﬁcant diﬀerence in the amount of
insulin per gram of pancreatic tissue between normal
and hypox rats, with the values being 188.7±20.7 lg/g
and 176.0±7.7 lg/g, respectively (Fig. 1g), but when
expressed per whole pancreas, hypox rats had a signiﬁ-
cantly lower insulin content than normal rats (46.9±2.3
Fig. 2 Localization of glucagon
peptide (a, b) and mRNA (c, d)
in normal (a, c) and
hypophysectomized (hypox) (b,
d) rats. Bar: 60 lm. Serum
glucagon (e), pancreatic
glucagon peptide content (f),
and glucagon mRNA levels (g)
of normal and hypox rats.
Serum and pancreatic glucagon
were measured by a speciﬁc rat
glucagon RIA, and glucagon
mRNA was determined by
Northern blot analysis.
Northern blot signals for
glucagon mRNA and 18S
rRNA are shown above the
corresponding columns for each
of the two groups (g). Glucagon
mRNA signals were normalized
against 18S rRNA signals and
expressed as relative levels.
Columns give the mean values
(n=6), and bars represent
SEM. Signiﬁcance levels are
shown in e–g
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vs. 81.6±10.9 lg per whole pancreas, respectively;
P=0.0197) due to lower pancreas weights. Northern
blot analysis showed a 2.6-fold increase in insulin
mRNA expression in the pancreas from hypox com-
pared with normal rats (P=0.0002, Fig. 1h).
Serum glucagon concentrations and pancreatic glucagon
peptide and mRNA levels
Serum glucagon concentrations were higher in hypox
(41.8±6.0 pmol/l) than in normal rats (26.6±2.6 pmol/
l; P=0.0415; Fig. 2e). Similarly, immunoreactive
glucagon per gram of pancreatic tissue was higher in
hypox (11.15±0.94 lg/g) than in normal animals
(8.34±0.75 lg/g; P=0.0416; Fig. 2f). However, there
was no statistical diﬀerence in the total pancreatic
glucagon content per pancreas between hypox and
normal animals (3.1±0.3 vs. 3.6±0.3 lg per pancreas,
respectively, P=0.294). By Northern blot analysis,
pancreatic glucagon mRNA levels were found to in-
crease in hypox rats (3.6±0.55) compared with normal
rats (0.85±0.08; P=0.0005; Fig. 2g).
Pancreatic somatostatin peptide and mRNA levels
The pancreatic somatostatin peptide content was higher
in hypox (1.18±0.15 lg/g) than in normal rats
(0.34±0.05 lg/g; P=0.0009; Fig. 3e), whether ex-
pressed per gram of tissue (1.18±0.15 lg/g vs.
0.34±0.05 lg/g) or per whole pancreas (333±50 vs.
Fig. 3 Localization of
somatostatin peptide (a, b) and
mRNA (c, d) in normal (a, c)
and hypophysectomized
(hypox) (b, d) rats. Bar: 60 lm.
Pancreatic somatostatin peptide
(e) and mRNA (f) levels of
normal and hypox rats.
Pancreatic somatostatin was
measured using an RIA against
human somatostatin.
Somatostatin mRNA was
determined by Northern blot
analysis. Northern blot signals
for somatostatin mRNA and
18S rRNA are shown above the
corresponding columns for each
of two groups (f). Somatostatin
mRNA signals were normalized
against 18S rRNA signals and
expressed as relative levels.
Columns give the mean values
(n=6), and bars represent
SEMs. Signiﬁcance levels are
shown in e and f
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139±22 ng per pancreas, respectively, P=0.0091). This
increase was accompanied by a 2.2-fold increase in
somatostatin mRNA (P<0.0001; Fig. 3f).
Serum IGF-I concentrations and pancreatic IGF-I
peptide and mRNA levels
Hypophysectomy caused a 11.7-fold decrease in total
serum IGF-I (161±15 ng/ml vs. 1,881±201 ng/ml in
normal rats; P<0.0001, Fig. 4c). In order to correct
the pancreatic IGF-I content for the IGF-I present in
the blood of tissue capillaries, we measured the blood
fraction in the pancreas of normal rats. Normal pan-
creatic tissue contained 5.26±0.42% blood (mean ±
SEM, n=3). For hypox rats, this value was corrected
according to their smaller blood volume (87% of
normal) (Gemzell and Sjostrand 1954). Based on a
mean hematocrit of 46%, the mean serum volume in
1 g of normal pancreas was 28.40±2.25 ll and 24 ll
in 1 g of hypox pancreas . Therefore, all IGF-I values
obtained for pancreatic extracts were corrected for
IGF-I present in the above serum volumes. The pan-
creatic IGF-I content in hypox rats was, therefore,
54% of that in the pancreas of normal animals
(184±9 vs. 338±26 ng/g, respectively; P=0.0002,
Fig. 4d). When expressed per whole pancreas, the
IGF-I content was 51.0±2.8 ng per pancreas for hy-
pox compared with 143±8 for normal rats. The de-
crease in IGF-I in serum and pancreatic tissue after
hypophysectomy was accompanied by a pronounced
decrease in pancreatic IGF-I mRNA levels (P=0.0023,
Fig. 4e).
Discussion
In this study, we investigated the eﬀect of hypophysec-
tomy in rats on the pancreatic peptide and mRNA levels
of the three major islet hormones insulin, glucagon, and
somatostatin, and possibly related changes in serum
glucose, insulin, and glucagon. Hypophysectomy was
carried out in 5-week-old animals, which were used
2 weeks later. Beside growth failure, a dramatic fall in
the serum IGF-I level reﬂected GH deﬁciency.
The drop in serum IGF-I was accompanied by a
decrease in immunoreactive pancreatic IGF-I, as as-
sessed by immunoﬂuorescence, which localized IGF-I to
Fig. 4 Localization of IGF-I
peptide in a normal and b
hypophysectomized (hypox)
rats. Bar: 60 lm. Serum IGF-I
(c), pancreatic IGF peptide
content (d), and IGF-I mRNA
levels (e) of normal and hypox
rats. Serum and pancreatic
IGF-I were measured by RIA.
IGF-I mRNA was determined
by Northern blot. IGF-I
mRNA and 18S rRNA signals
are shown above the
corresponding columns for each
of two groups (e). IGF-I
mRNA signals were normalized
against the 18S rRNA signals
and expressed as relative levels.
Columns give the mean values
(n=5), and bars indicate SEM.
Signiﬁcance levels are shown in
c–e
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the a cells of the islets (Maake and Reinecke 1993; Je-
vdjovic et al. 2004), and by radioimmunological deter-
mination of IGF-I in pancreas extracts. Furthermore, a
concomitant decrease in IGF-I mRNA was documented
by Northern blot analysis. The decrease in pancreatic
IGF-I peptide and mRNA was less dramatic than the
decrease in serum IGF-I, indicating that GH deﬁciency
primarily aﬀects the liver, the main production site of
IGF-I. Nevertheless, the speciﬁc localization of IGF-I in
a cells, as well as the GH-dependent regulation of IGF-I
peptide in these cells and of the pancreatic IGF-I mRNA
(Jevdjovic et al. 2004), suggests that IGF-I is produced
in the pancreatic islets. Another study has shown that
IGF-I is also secreted from rat pancreatic islets (Swenne
and Hill 1989).
The reduced serum insulin and elevated glucagon
concentrations observed in our study agree with earlier
ﬁndings in hypox rats (Van Lan et al. 1974). Despite
decrease in serum insulin, serum glucose and pancre-
atic insulin content per gram of tissue were not sig-
niﬁcantly diﬀerent from the normal animals, as also
reported by Malaisse et al. (1968), and the insulin
mRNA level was elevated, as demonstrated by ISH
and Northern blot analysis. These ﬁndings might be
interpreted as a reﬂection of reduced translational
eﬃciency together with a blunted insulin response to
glucose due to the lack of GH. Several studies have
shown that the insulin response to glucose is delayed
and/or reduced in hypox-rat-isolated islets (Parman
1975) or in hypox rats in vivo (Penhos et al. 1971;
Heinze et al. 1981). In another study, the ﬁrst and
second phase of insulin secretion in the perfused
pancreas of hypox rats have been found to be de-
pressed (Curry and Bennett 1973).
In the hypox rats, 1.3-fold elevated glucagon content
per gram of pancreas, as measured by RIA and quali-
tatively conﬁrmed by IHC, was paralleled by a similar
(1.6-fold) increase in serum glucagon whereas glucagon
mRNA by both Northern blot analysis and ISH showed
a more pronounced rise (4.5-fold by Northern blot
analysis). When comparing the relative ratios between
glucagon mRNA and peptide in normal (1:10) and hy-
pox rats (1:3), it appears that the translational eﬃciency
is reduced in the hypox animals. The corresponding
ratios for insulin mRNA and peptide (1:110 in normal
rats and 1:40 in hypox rats) also support this reasoning,
as mentioned earlier.
GH regulates its own secretion by regulating the
synthesis and secretion of somatostatin in the hypo-
thalamus (Giustina and Veldhuis 1998). Thus, GH
deﬁciency after hypophysectomy results in a decrease in
the hypothalamic somatostatin content in vivo and its
release in vitro (Berelowitz et al. 1981). In contrast,
pancreatic somatostatin has been reported to be in-
creased in rats 4–6 weeks after hypophysectomy (Recant
et al. 1984). The latter result agrees with the results of
the present study with respect to the pancreatic
somatostatin peptide content. In addition, we also show
that somatostatin mRNA, as assessed by two diﬀerent
methods, was signiﬁcantly increased. Unfortunately, it
was not possible to measure serum somatostatin because
the serum volume required for this RIA (5 ml) by far
exceeded the amount obtained from one rat. It appears
from the above-mentioned relative ratios between
somatostatin peptide and mRNA that the translational
eﬃciency was increased rather than decreased in hypox
(1:320) compared with normal (1:200) animals.
In summary, the results of our study show that the
fall of serum IGF-I after hypophysectomy goes along
with a concomitant decrease of pancreatic IGF-I peptide
and mRNA but with partly discordant changes of the
serum concentrations of insulin and glucagon and the
islet peptide and/or mRNA content of the three major
islet hormones. It appears that GH deﬁciency resulting
in a ‘‘low IGF-I state’’ aﬀects translational eﬃciency of
these hormones as well as their secretory responses. Fi-
nally, the maintenance of normoglycemia in the presence
of reduced serum insulin and elevated serum glucagon
concentrations, both of which would be expected to raise
the blood sugar level, may result mainly from enhanced
insulin sensitivity of insulin target tissues, possibly due
to GH deﬁciency and the subsequent decrease of IGF-I
production (Yakar et al. 2004).
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